- How To
- Cigar Info
- Site Info
Currently viewing the tag: "top"
US e-cigarette unit sales generally increased as product prices decreased. These findings demonstrate the rapidly evolving landscape of US e-cigarette retail marketplace. Ongoing surveillance of e-cigarette unit sales and price is critical for informing a
In the case of smoking, American corporations were selling cigarettes to turn a profit. Today, however, foreign actors are deploying misleading content to actively undermine our democracy. For this reason, the FBI and other U.S. intelligence agencies shou
FDA may regulate “premium” cigars differently from other cigars, so long as the differences are science- and evidence-based and FDA applies objective criteria to allow for predictable and fair application of its authority.
In a letter sent to the [FDA], Altria—the $25 billion company behind Marlboro cigarettes, the parent of Nat Sherman, and the largest tobacco concern in the United States—asked the FDA to not exempt the small, handmade premium cigar industry from its toba
The company is planning to launch a Bluetooth-enabled vaping device internationally, which could prevent younger users from smoking. It comes as Juul continues to face growing backlash over whether or not it expressly targeted teens in its marketing an
Juul Labs Inc. came out swinging against a possible across-the-board prohibition on flavored tobacco, claiming it would be a detriment to adult smokers wanting to switch from cigarettes and could even drive U.S. consumers into an illicit “gray market.”
Venture Corp. has lost over a third of its market value…concerns over possible fallout from slower sales of Philip Morris’ smokeless cigarette devices that the Singapore company is believed to be contracted to help make.
Enforcing residential bans on smoking could help large numbers of low-income people quit smoking, according to an analysis of federally funded national surveys by a California research team. The finding comes as public housing authorities across the count
The public comment periods for all three ANPRMs, which were extended by 30 additional days to allow more time for submissions, have now closed. We are beginning the process of reviewing those comments. At the same time, the FDA is also pursuing additional